Overcoming Ovarian Cancer Chemoresistance

Overcoming Ovarian Cancer Chemoresistance
Author: Goli Samimi,Christina Annunziata
Publsiher: Academic Press
Total Pages: 188
Release: 2020-11-06
ISBN 10: 0128198419
ISBN 13: 9780128198414
Language: EN, FR, DE, ES & NL

Overcoming Ovarian Cancer Chemoresistance Book Review:

Overcoming Ovarian Cancer Chemoresistance presents non-overlapping review chapters that discuss the state of the field in overcoming chemoresistance of ovarian cancer and treatment options before and following recurrence, considering the genetic makeup of the ovarian cancer patient and her tumor. With the uptake of both germline and somatic gene testing, clinicians can obtain a more comprehensive understanding of ovarian tumors and this book provides information to link the genetic makeup of a tumor (or patient) with the best available treatment. The book discusses topics such as strategies to fight chemo-resistance in ovarian cancer, circulating DNA as a monitor of response, BRCA mutations, ovarian cancer stem cells, immunotherapy and vaccines. Additionally, it brings a list of promising agents at clinical and pre-clinical stage that will impact the treatment in the near future. This book is a valuable source for cancer researchers, oncologists and several members of biomedical field who need to understand how to battle chemoresistance in ovarian cancer. Provides a comprehensive view of both biological and genetic determinants of resistance, as well as technical approaches to monitor response Discusses genetic reversions as a unique alteration and a new field of study Includes a chapter on upcoming and promising agents that are in the pre-clinical and early clinical space, to set the stage for future directions in the field

Overcoming Drug Resistance in Gynecologic Cancers

Overcoming Drug Resistance in Gynecologic Cancers
Author: Anonim
Publsiher: Academic Press
Total Pages: 300
Release: 2021-05-15
ISBN 10: 9780128242995
ISBN 13: 012824299X
Language: EN, FR, DE, ES & NL

Overcoming Drug Resistance in Gynecologic Cancers Book Review:

Overcoming Drug Resistance in Gynecologic Cancers provides up-to-date information related to important gynecologic cancers and focuses on mechanisms of drug resistance, genetics, signaling, immunology, health disparities, nanotechnology, economic considerations and financial impacts. The book covers not only drug resistance but also important means to reverse resistance both in the laboratory and clinic. The book discusses topics such as lifestyle, nutrition and risk of gynecologic cancers, the financial impact of drug resistance, chemosensitizing agents and targeted therapies in cervical, endometrial and ovarian cancer, immunotherapy to overcome drug resistance, and genetic polymorphisms in gynecologic cancers. Additionally, it discusses ethnic and racial health disparity perspectives and future developments in chemosensitizing activities to reverse drug resistance in gynecologic cancers. It is a valuable resource for cancer researchers, oncologists, clinicians and other biomedical field members who are interested in new approaches to improve chemotherapy outcome in patients with gynecologic cancers. Provides a comprehensive resource with all the details needed for readers to understand and follow information Encompasses schematics, diagrams and flow charts in all chapters to help readers easily follow critical information Presents tables and figures especially developed to summarize the information with appropriate statistical rigor and to show details of clinical specimens such as pathological, radiological characteristics, and/or laboratory biomarkers

Cancer Cell Chemoresistance and Chemosensitization

Cancer Cell Chemoresistance and Chemosensitization
Author: Ajaikumar B. Kunnumakkara,Devivasha Bordoloi,Javadi Monisha
Publsiher: World Scientific
Total Pages: 329
Release: 2018
ISBN 10: 9813208570
ISBN 13: 9789813208575
Language: EN, FR, DE, ES & NL

Cancer Cell Chemoresistance and Chemosensitization Book Review:

Biological Mechanisms and the Advancing Approaches to Overcoming Cancer Drug Resistance

Biological Mechanisms and the Advancing Approaches to Overcoming Cancer Drug Resistance
Author: Andrew Freywald,Franco Vizeacoumar
Publsiher: Academic Press
Total Pages: 308
Release: 2020-12-04
ISBN 10: 0128213116
ISBN 13: 9780128213117
Language: EN, FR, DE, ES & NL

Biological Mechanisms and the Advancing Approaches to Overcoming Cancer Drug Resistance Book Review:

Biological Mechanisms and the Advancing Approaches to Overcoming Cancer Drug Resistance, Volume 12, discusses new approaches that are being undertaken to counteract tumor plasticity, understand and tackle the interactions with the microenvironment, and disrupt the rewiring of malignant cells or bypass biological mechanism of resistance by using targeted radionuclide therapies. This book provides a unique opportunity to the reader to understand the fundamental causes of drug resistance and how different approaches are applied. It is a one-stop-shop to understand why it is so difficult to treat cancer, and why only a very few patients respond to therapy and a significant portion develop resistance. Despite a rapid development of more effective anti-cancer drugs and combination therapies, cancer remains the leading cause of lethality in the developed world. The main reason for this is the ability of heterogeneous subpopulations of tumor cells interacting with constantly evolving tumor microenvironment to resist elimination and eventually, trigger cancer relapse. In this book, experts review current concepts explaining molecular and biological mechanisms of cancer drug resistance and discussing advancing approaches for overcoming these therapeutic challenges. Provides the most updated knowledge on the mechanisms of cancer drug resistance and the emerging therapeutic approaches reviewed by experts in the field Brings detailed analyses of most important recently reported developments related to drug resistance and their relevance to overcoming it in cancer patients Discusses in-depth molecular mechanisms and novel concepts of cancer resistance to conventional and advanced therapies

Ovarian Cancer

Ovarian Cancer
Author: Omer Devaja,Andreas Papadopoulos
Publsiher: BoD – Books on Demand
Total Pages: 364
Release: 2018-10-24
ISBN 10: 1789843332
ISBN 13: 9781789843330
Language: EN, FR, DE, ES & NL

Ovarian Cancer Book Review:

Ovarian cancer management is a rapidly changing field with new treatment agents available as a result of a greater understanding of the pathogenesis of this disease. In addition, both surgical and chemotherapeutic treatment strategies are evolving to maximise response in this disease. This book brings together leading specialists from around the world to discuss and outline a variety of new concepts in ovarian cancer, ranging from molecular biology and genetics through screening to both surgical and chemotherapeutic management.

Cancer Drug Resistance Research Perspectives

Cancer Drug Resistance Research Perspectives
Author: Liman S. Torres
Publsiher: Nova Publishers
Total Pages: 223
Release: 2007
ISBN 10: 9781600215728
ISBN 13: 1600215726
Language: EN, FR, DE, ES & NL

Cancer Drug Resistance Research Perspectives Book Review:

One of the main causes of failure in the treatment of cancer is the development of drug resistance by the cancer cells. The design of cancer chemotherapy has become increasingly sophisticated, yet there is no cancer treatment that is 100% effective against disseminated cancer. Resistance to treatment with anticancer drugs results from a variety of factors including individual variations in patients and somatic cell genetic differences in tumours, even those from the same tissue of origin. Frequently resistance is intrinsic to the cancer, but as therapy becomes more and more effective, acquired resistance has also become common. The most common reason for acquisition of resistance to a broad range of anticancer drugs is expression of one or more energy-dependent transporters that detect and eject anticancer drugs from cells, but other mechanisms of resistance including insensitivity to drug-induced apoptosis and induction of drug-detoxifying mechanisms probably play an important role in acquired anticancer drug resistance. Studies on mechanisms of cancer drug resistance have yielded important information about how to circumvent this resistance to improve cancer chemotherapy and have implications for pharmacokinetics of many commonly used drugs. This book presents new and important research in this field.

Fast Facts Ovarian Cancer

Fast Facts  Ovarian Cancer
Author: Christina Fotopoulou,Thomas J. Herzog
Publsiher: Karger Medical and Scientific Publishers
Total Pages: 102
Release: 2017-05-09
ISBN 10: 191079743X
ISBN 13: 9781910797433
Language: EN, FR, DE, ES & NL

Fast Facts Ovarian Cancer Book Review:

When it comes to detecting, diagnosing and treating women who have, or are suspected of having, ovarian cancer, there are significant opportunities for well-informed healthcare professionals to intervene in a meaningful way. 'Fast Facts: Ovarian Cancer' examines the areas that will have the biggest effect in clinical practice, including: • the evidence for and against screening • the valuable role of genetic testing in identifying at-risk women • if and when to operate • strategies to overcome platinum resistance • the impact of targeted therapies. From the tools that will help establish a swift diagnosis to the risks and benefits of palliative salvage surgery, this refreshingly readable resource captures the key knowledge that every busy healthcare professional needs in order to make better health decisions for patients with ovarian cancer. Contents: • Epidemiology and prevention • Pathophysiology and classification • Genetic testing • Diagnosis, staging and grading • Surgery • Chemotherapy • Recurrent ovarian cancer • Targeted therapies • Non-epithelial ovarian cancers • Follow-up and palliative surgery • Useful resources

Therapeutic Strategies to Overcome ALK Resistance in Cancer

Therapeutic Strategies to Overcome ALK Resistance in Cancer
Author: Luc Friboulet
Publsiher: Academic Press
Total Pages: 216
Release: 2021-01-18
ISBN 10: 0128217790
ISBN 13: 9780128217795
Language: EN, FR, DE, ES & NL

Therapeutic Strategies to Overcome ALK Resistance in Cancer Book Review:

Therapeutic Strategies to Overcome ALK Resistance in Cancer, Volume 13, presents current strategies to improve and prolong clinical benefit in ALK driven cancers. Most patients with ALK-driven cancer are sensitive to tyrosine kinase inhibitor (TKI) therapy, but resistance invariably develops. This book discusses topics such as structure and function of ALK, ALK rearranged lung cancer, resistance mechanisms to ALK TKI tumors, and novel therapeutic strategies to enhance crizotinib anti-tumor efficacy in ALCL. Additionally, it encompasses information on drug combinations to enhance ALK TKI anti-tumor efficacy in neuroblastoma and future perspectives in the field. This book is a valuable resource for cancer researchers, clinicians and several members of biomedical field who need to understand more about how to fight ALK resistance in cancer treatment. Explains the biology of ALK RTK, focusing on its tissue expression, structure and functionality Presents an overview of current treatments and the benefits of ALK TKI in lung and other cancer types, such as ALCL, neuroblastoma and inflammatory myofibroblastic tumor Encompasses information on systemic treatments other than TKI, including chemotherapy, immunotherapy and antiangiogenic agents in ALK-driven NSCLC

Overcome the Challenges of Cancer Care

Overcome the Challenges of Cancer Care
Author: Stephen A. Rosenberg,Stephen M D Rosenberg
Publsiher: Rowman & Littlefield Publishers
Total Pages: 160
Release: 2020
ISBN 10: 1538134233
ISBN 13: 9781538134238
Language: EN, FR, DE, ES & NL

Overcome the Challenges of Cancer Care Book Review:

"A friendly, easy-to-read guide for cancer patients and their loved ones when dealing with a cancer diagnosis. This book will help patients, loved ones, friends and family recognize the pitfalls of a cancer diagnosis and how to avoid them to get the best care possible during their cancer journey"--

Progress in Cancer Drug Resistance Research

Progress in Cancer Drug Resistance Research
Author: Robert A. Parsons
Publsiher: Nova Publishers
Total Pages: 223
Release: 2007
ISBN 10: 9781600218224
ISBN 13: 1600218229
Language: EN, FR, DE, ES & NL

Progress in Cancer Drug Resistance Research Book Review:

One of the main causes of failure in the treatment of cancer is the development of drug resistance by the cancer cells. The design of cancer chemotherapy has become increasingly sophisticated, yet there is no cancer treatment that is 100 percent effective against disseminated cancer. Resistance to treatment with anticancer drugs results from a variety of factors including individual variations in patients and somatic cell genetic differences in tumours, even those from the same tissue of origin. Frequently resistance is intrinsic to the cancer, but as therapy becomes more and more effective, acquired resistance has also become common.The most common reason for acquisition of resistance to a broad range of anticancer drugs is expression of one or more energy-dependent transporters that detect and eject anti-cancer drugs from cells, but other mechanisms of resistance including insensitivity to drug-induced apoptosis and induction of drug-detoxifying mechanisms probably play an important role in acquired anticancer drug resistance. Studies on mechanisms of cancer drug resistance have yielded important information on how to circumvent this resistance to improve cancer chemotherapy and have implications for pharmacokinetics of many commonly used drugs.

Ovarian Cancers

Ovarian Cancers
Author: National Academies of Sciences, Engineering, and Medicine,Institute of Medicine,Board on Health Care Services,Committee on the State of the Science in Ovarian Cancer Research
Publsiher: National Academies Press
Total Pages: 396
Release: 2016-05-25
ISBN 10: 0309380464
ISBN 13: 9780309380461
Language: EN, FR, DE, ES & NL

Ovarian Cancers Book Review:

In an era of promising advances in cancer research, there are considerable and even alarming gaps in the fundamental knowledge and understanding of ovarian cancer. Researchers now know that ovarian cancer is not a single disease-several distinct subtypes exist with different origins, risk factors, genetic mutations, biological behaviors, and prognoses. However, persistent questions have impeded progress toward improving the prevention, early detection, treatment, and management of ovarian cancers. Failure to significantly improve morbidity and mortality during the past several decades is likely due to several factors, including the lack of research being performed by specific disease subtype, lack of definitive knowledge of the cell of origin and disease progression, and incomplete understanding of genetic and non-genetic risk factors. Ovarian Cancers examines the state of the science in ovarian cancer research, identifies key gaps in the evidence base and the challenges to addressing those gaps, considers opportunities for advancing ovarian cancer research, and examines avenues for translation and dissemination of new findings and communication of new information to patients and others. This study makes recommendations for public- and private-sector efforts that could facilitate progress in reducing the incidence of morbidity and mortality from ovarian cancers.

Cancer Drug Resistance

Cancer Drug Resistance
Author: Thomas C. Hall
Publsiher: Unknown
Total Pages: 235
Release: 1986
ISBN 10:
ISBN 13: UOM:39015011479253
Language: EN, FR, DE, ES & NL

Cancer Drug Resistance Book Review:

Chemosensitivity Testing in Oncology

Chemosensitivity Testing in Oncology
Author: Uwe Reinhold,Wolfgang Tilgen
Publsiher: Springer Science & Business Media
Total Pages: 245
Release: 2002-10-31
ISBN 10: 9783540434689
ISBN 13: 3540434682
Language: EN, FR, DE, ES & NL

Chemosensitivity Testing in Oncology Book Review:

Over the past 50 years many in vitro and in vivo drug response assay systems have been developed to determine the potential - tivity of chemotherapy agents. The idea was to eliminate ineffective agents and unnecessary toxic treatment while selecting drugs active in vitro or in the mouse model that might increase the probability of response in the patient. None of these test models, however, achieved routine clinical application in the past. This might be at least in part - lated to large discrepancies that were described between the s- cess rate of the assay systems and the clinical benefit in cancer - tients. The heterogeneity of chemosensitivity that exists between different tumors as well as between individual tumor lesions may be one explanation for these findings. Furthermore, different assay end points such as proliferation, metabolism, and vitality were - veloped to evaluate the effects of cytostatic drugs on tumor cells, and these might be related to the differing results. However, knowledge about procedures for assay-assisted treatment selection has increased rapidly within the past few years, and several studies suggest that test-directed chemotherapy selection now may - prove response rates and survival in various types of tumors. The International Society for Chemosensitivity Testing in - cology (ISCO) was founded to promote, coordinate, and improve clinical and laboratory research in the field of predictive drug te- ing in human tumor cells.

The Tumor Microenvironment of High Grade Serous Ovarian Cancer

The Tumor Microenvironment of High Grade Serous Ovarian Cancer
Author: M. Sharon Stack,Kenneth P. Nephew,Joanna E. Burdette,Anirban K. Mitra
Publsiher: MDPI
Total Pages: 434
Release: 2019-02-06
ISBN 10: 3038975540
ISBN 13: 9783038975540
Language: EN, FR, DE, ES & NL

The Tumor Microenvironment of High Grade Serous Ovarian Cancer Book Review:

This book is a printed edition of the Special Issue "The Tumor Microenvironment of High Grade Serous Ovarian Cancer" that was published in Cancers

Heparanase

Heparanase
Author: Israel Vlodavsky,Ralph D. Sanderson,Neta Ilan
Publsiher: Springer Nature
Total Pages: 885
Release: 2020-04-09
ISBN 10: 3030345211
ISBN 13: 9783030345211
Language: EN, FR, DE, ES & NL

Heparanase Book Review:

Written by internationally recognized leaders in Heparanase biology, the book’s eight chapters offer an opportunity for scientists, clinicians and advanced students in cell biology, tumor biology and oncology to obtain a comprehensive understanding of Heparanase’s multifaceted activities in cancer, inflammation, diabetes and other diseases, as well as its related clinical applications. Proteases and their involvement in cancer progression have been well addressed and documented; however, the emerging premise presented within this book is that Heparanase is a master regulator of aggressive cancer phenotypes and crosstalk with the tumor microenvironment. This endoglycosidase contributes to tumor-mediated remodeling of the extracellular matrix and cell surfaces, augmenting the bioavailability of pro-tumorigenic and pro-inflammatory growth factors and cytokines that are bound to Heparan sulfate. Compelling evidence ties Heparanase with all steps of tumor progression including tumor initiation, growth, angiogenesis, metastasis, and chemoresistance, supporting the notion that Heparanase is an important contributor to the poor outcome of cancer patients and a validated target for therapy. Unlike Heparanase, heparanase-2, a close homolog of Heparanase, lacks enzymatic activity, inhibits Heparanase, and regulates selected genes that promote normal differentiation and tumor suppression. Written by internationally recognized leaders in Heparanase biology, this volume presents a comprehensive understanding of Heparanase’s multifaceted activities in cancer, inflammation, diabetes and other diseases, as well as its related clinical applications to scientists, clinicians and advanced students in cell biology, tumor biology and oncology.

Ascites

Ascites
Author: Luis Rodrigo
Publsiher: BoD – Books on Demand
Total Pages: 174
Release: 2017-11-29
ISBN 10: 9535136135
ISBN 13: 9789535136132
Language: EN, FR, DE, ES & NL

Ascites Book Review:

The term "ascites" is from the Greek word askites meaning "baglike." Although most commonly due to cirrhosis, severe liver disease or metastatic cancer, its presence can be a sign of other significant medical problems, such as Budd-Chiari syndrome. Diagnosis of the cause is usually done with blood tests, an ultrasound scan of the abdomen, and direct removal of the fluid by a needle or paracentesis (which may also be therapeutic). Treatment using medications (diuretics), external drainage, or other treatments is clearly defined. In this book, the authors describe the physiopathology of the diverse causes of ascites,the types of treatments recommended, the recent advances achieved, the complications and the prognosis of the different clinical situations that doctors must face.

Cancer Drug Resistance

Cancer Drug Resistance
Author: Beverly A. Teicher
Publsiher: Springer Science & Business Media
Total Pages: 617
Release: 2007-11-09
ISBN 10: 1597450359
ISBN 13: 9781597450355
Language: EN, FR, DE, ES & NL

Cancer Drug Resistance Book Review:

Leading experts summarize and synthesize the latest discoveries concerning the changes that occur in tumor cells as they develop resistance to anticancer drugs, and suggest new approaches to preventing and overcoming it. The authors review physiological resistance based upon tumor architecture, cellular resistance based on drug transport, epigenetic changes that neutralize or bypass drug cytotoxicity, and genetic changes that alter drug target molecules by decreasing or eliminating drug binding and efficacy. Highlights include new insights into resistance to antiangiogenic therapies, oncogenes and tumor suppressor genes in therapeutic resistance, cancer stem cells, and the development of more effective therapies. There are also new findings on tumor immune escape mechanisms, gene amplification in drug resistance, the molecular determinants of multidrug resistance, and resistance to taxanes and Herceptin.

Anticancer Research

Anticancer Research
Author: Anonim
Publsiher: Unknown
Total Pages: 329
Release: 2010
ISBN 10:
ISBN 13: UCSD:31822036999886
Language: EN, FR, DE, ES & NL

Anticancer Research Book Review:

PIPAC

PIPAC
Author: Marc A. Reymond,Wiebke Solass
Publsiher: Walter de Gruyter GmbH & Co KG
Total Pages: 252
Release: 2014-10-14
ISBN 10: 3110366614
ISBN 13: 9783110366617
Language: EN, FR, DE, ES & NL

PIPAC Book Review:

Peritoneal dissemination is a common route of cancer metastasis. The benefit of administering chemotherapy directly into the peritoneal cavity is supported by preclinical and pharmacokinetic data. In comparison to intravenous (IV) treatment, intraperitoneal (IP) administration results in a several-fold increase in drug concentration within the abdominal cavity. There is now growing evidence from clinical studies showing a survival advantage for IP chemotherapy in various tumor typies, including ovarian, gastric and colorectal cancer. However, while the use of IP chemotherapy is slowly gaining acceptance, it is not universal, largely due to the greater toxicity associated with this approach. Moreover, efficacy of IP chemotherapy is limited by poor distribution within the abdominal cavity and by poor tissue penetration. A new way of IP chemotherapy is the application of cytotoxics in form of a pressurized aerosol into the abdominal of thoracic cavity. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is applied through laparoscopic access using two balloon trocars in an operating room equipped with laminar air-flow. In a first step,a normothermic capnoperitoneum is established with a pressure of 12 mmHg. A cytotoxic solution (about 10% of a normal systemic dose) is nebulized with a micropump into the abdominal cavity, and maintained for 30 min. The aerosol is then removed through a closed suction system. Applying an aerosol in the peritoneal cavity allows a homogeneous distribution of the chemotherapeutic agent within the abdomen. Furthermore, an artificial pressure gradient is generated that overcomes tumoral interstitial fluid pressure, an obstacle in cancer therapy. This results in a higher local drug concentration compared to conventional IP or IV chemotherapy. At the same time the plasma concentration of the chemotherapeutic agent remains low. In first clinical studies with limited number of patients in ovarian, gastric and colorectal cancer, as well as peritoneal mesothelioma, PIPAC has obtained encouraging tumor response rates and survival, with a low-side effects profile. Larger clinical trials are currently ongoing to examine if these data can be reproduced and extrapolated to other situations.

Beating Ovarian Cancer

Beating Ovarian Cancer
Author: Chris Bledy
Publsiher: Chris Bledy
Total Pages: 224
Release: 2008
ISBN 10: 9781890427672
ISBN 13: 1890427675
Language: EN, FR, DE, ES & NL

Beating Ovarian Cancer Book Review:

A diagnosis of Ovarian Cancer does not have to be a death sentence. Recent advances in medicine have made this once incurable disease treatable and manageable. You can beat advanced and even recurring, ovarian cancer. Simple but significant lifestyle changes can produce big results when it comes to healing.